Cytokinetics, Incorporated (CYTK)
CYTK moved a median of +0.02% 30 minutes after news, and +0.18% by the close. How CYTK actually reacts to news — the realized, point-in-time move the market made, measured across 1,706 labeled events over the last three years with zero look-ahead.
CYTK’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 49% | 1,704 |
| 30-min | +0.02% | 50% | 1,706 |
| 60-min | -0.05% | 49% | 1,706 |
| to close | +0.18% | 54% | 1,686 |
| Middle 50% of CYTK reactions | -0.77% to +1.06% |
|---|---|
| Median reaction (30-min) | +0.02% |
| Measured reactions | 1,706 |
Half of all Cytokinetics, Incorporated news events land between -0.77% and +1.06% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How CYTK reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 19 | -0.60% | 42% | -0.67% |
| Analyst downgrades | 11 | +0.22% | 64% | +2.43% |
| Coverage initiations | 25 | -0.34% | 44% | +0.65% |
| Rating reiterations | 212 | 0.00% | 50% | 0.00% |
| Price-target raises | 36 | +0.45% | 61% | +0.15% |
| Price-target cuts | 20 | -0.44% | 35% | -0.49% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how CYTK ranks against every other measured name →
That’s how CYTK usually reacts — get an email when it moves on news →Email me when CYTK moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CYTK's baseline. Nothing else.
Recent CYTK events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026 | Press release | GlobeNewswire | +0.85% | -1.12% | |
| Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026 | Press release | GlobeNewswire | -0.48% | -1.28% | |
| Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy | Press release | GlobeNewswire | +0.92% | +0.01% | |
| Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.61% | -2.00% | |
| Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program | Press release | GlobeNewswire | +0.73% | -1.79% | |
| Cytokinetics to Participate in September Investor Conferences | Press release | GlobeNewswire | +0.21% | +2.71% | |
| Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026 | Press release | GlobeNewswire | -1.49% | -0.85% | |
| Cytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England Journal of Medicine | Press release | GlobeNewswire | -0.54% | -2.96% | |
| Form 8-K CYTOKINETICS INC For: Aug 28 | SEC filing · Form 8-K | SEC EDGAR | -0.54% | -2.96% | |
| Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026 | Press release | GlobeNewswire | -0.48% | -0.23% | |
| Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.52% | +0.66% | |
| Form 8-K CYTOKINETICS INC For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +0.73% | +2.67% | |
| Form 8-K CYTOKINETICS INC For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | -1.23% | -4.36% | |
| Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | -3.47% | -5.50% | |
| Form 10-Q CYTOKINETICS INC For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.47% | -5.50% | |
| Form 8-K CYTOKINETICS INC For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | -3.47% | -5.50% | |
| Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®? (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales | Press release | GlobeNewswire | +1.10% | +2.59% | |
| Cytokinetics to Announce Second Quarter Results on August 6, 2026 | Press release | GlobeNewswire | -0.41% | -2.24% | |
| Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.05% | -1.65% | |
| Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026 | Press release | GlobeNewswire | -0.93% | -1.09% | |
| Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.01% | -0.79% | |
| Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program | Press release | GlobeNewswire | -1.38% | -5.69% | |
| Cytokinetics to Participate in June Investor Conferences | Press release | GlobeNewswire | -0.74% | -0.61% | |
| Form 8-K CYTOKINETICS INC For: May 27 | SEC filing · Form 8-K | SEC EDGAR | -0.74% | -0.61% | |
| Form S-8 CYTOKINETICS INC | SEC filing · Form S-8 | SEC EDGAR | -0.74% | -0.61% | |
| Cytokinetics to Hold Annual Meeting of Stockholders | Press release | GlobeNewswire | -0.51% | -0.42% | |
| Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | Press release | GlobeNewswire | -2.29% | +1.06% | |
| Cytokinetics to Host Annual Symposium on Contemporary Landscapes in Muscle Biology (CLIMB) | Press release | GlobeNewswire | +0.87% | +2.01% | |
| Cytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference | Press release | GlobeNewswire | +0.26% | +3.29% | |
| Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026 | Press release | GlobeNewswire | -0.03% | -4.13% | |
| Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $805 Million | Press release | GlobeNewswire | +0.65% | -0.61% | |
| Form 8-K CYTOKINETICS INC For: May 06 | SEC filing · Form 8-K | SEC EDGAR | -0.22% | -3.99% | |
| Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock | Press release | GlobeNewswire | -1.09% | -0.24% | |
| Cytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy | Press release | GlobeNewswire | +3.22% | +3.46% | |
| Cytokinetics Announces Proposed Public Offering of Common Stock | Press release | GlobeNewswire | -1.45% | -4.05% | |
| Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | -1.45% | -4.05% | |
| Form 10-Q CYTOKINETICS INC For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.45% | -4.05% | |
| Form 8-K CYTOKINETICS INC For: May 05 | SEC filing · Form 8-K | SEC EDGAR | -1.45% | -4.05% | |
| Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy, on May 5, 2026 | Press release | GlobeNewswire | +3.22% | +3.46% | |
| Cytokinetics Announces Nine Upcoming Presentations at the European Society of Cardiology Heart Failure 2026 Congress | Press release | GlobeNewswire | +0.90% | -2.80% | |
| Cytokinetics to Announce First Quarter Results on May 5, 2026 | Press release | GlobeNewswire | -1.01% | -0.27% | |
| Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | Press release | GlobeNewswire | -1.67% | -0.32% | |
| Form ARS CYTOKINETICS INC For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.50% | -0.84% | |
| Form DEF 14A CYTOKINETICS INC For: May 27 | SEC filing · Form DEF | SEC EDGAR | -0.50% | -0.84% | |
| Cytokinetics to Participate in the 25th Annual Needham Virtual Healthcare Conference | Press release | GlobeNewswire | +0.15% | +1.13% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | -0.99% | -1.68% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +0.28% | +2.23% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.26% | +0.27% | |
| Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.71% | -3.25% | |
| Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | Press release | GlobeNewswire | -0.76% | +1.53% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CYTK section they belong to.
Where else CYTK is measured.
CYTK earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Capricor Therapeutics, Inc. (CAPR) | 1,806 | -0.20% | 45% |
| Spectrum Pharmaceuticals, Inc. (SPPI) | 1,780 | 0.00% | 48% |
| MYLAN NV ORDINARY SHARES (MYL) | 1,701 | -0.13% | 44% |
| Inspire Medical Systems, Inc. (INSP) | 1,692 | +0.06% | 53% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Cytokinetics, Incorporated's median reaction calculated?
Every labeled CYTK news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 1,706 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 50% of CYTK's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CYTK's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.